Counterpoint Mutual Funds LLC Invests $727,000 in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Counterpoint Mutual Funds LLC bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 156,439 shares of the company’s stock, valued at approximately $727,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. EP Wealth Advisors LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at approximately $73,000. Versor Investments LP acquired a new position in GoodRx during the fourth quarter worth $54,000. Verus Capital Partners LLC bought a new position in shares of GoodRx during the fourth quarter valued at $55,000. Steward Partners Investment Advisory LLC bought a new position in shares of GoodRx during the fourth quarter valued at $56,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of GoodRx in the 3rd quarter valued at $85,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Mizuho began coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price on the stock. Morgan Stanley dropped their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Citigroup reduced their price objective on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, KeyCorp decreased their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Trading Down 1.1 %

Shares of GoodRx stock opened at $4.42 on Monday. The firm has a market capitalization of $1.70 billion, a PE ratio of -147.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm’s 50 day moving average is $4.72 and its 200 day moving average is $5.51. GoodRx Holdings, Inc. has a 1 year low of $4.09 and a 1 year high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.